Lenvatinib

- Overview
  - Lenvatinib, the free base form of the compound, is a small-molecule multityrosine kinase inhibitor that inhibits many receptor tyrosine kinases including vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), and stem cell factor (SCF). These growth factors are associated with many types of cancers. The compound can inhibit angiogenesis (the formation of new vessels), and tumor cell growth.
    
    Please contact us at for specific academic pricing.
    
    Background
    
    Lenvatinib is a multiple kinase inhibitor. It inhibits VEGFR1, 2, and 3. It also inhibits FGFR 1, 2, 3 and 4. Some of these proteins play a role in cancer signaling pathways.
- Properties
  - CAS Number
    
    417716-92-8
    
    Molecular Formula
    
    C21H19ClN4O4
    
    Molecular Weight
    
    426.85
    
    Appearance
    
    Red-brown to white-like solid
    
    Solubility
    
    DMSO (40 mg/ml). Insoluble in water and ethanol.
    
    Other Properties
    
    Source: Synthetic
    Purity Level: ≥99% (by HPLC)
    
    Storage
    
    -20°C
    
    * For research use only
- Applications
  - Application Description
    
    Eukaryotic Cell Culture Applications: In vitro studies with human umbilical vein endothelial cells (HUVECs) (human SCLC cell lines NCI-H146 and NCI-H526), Lenvatinib inhibited angiogenesis that was induced by SCF and VEGF (Matsui et al, 2008).
    
    Cancer Applications: Lymph node metastases occur through lymphangiogenesis (formation of new lymphatic vessels) and metastases to distant organs occurs through angiogenesis (formation of new blood vessels). These phenomena are regulated by endothelial cell-specific growth factors such as VEGFs. In a xenograph model of human breast adenocarcinoma with MDA-MB-231 cells that express excessive VEGF-C, Lanvatinib was found to inhibit tumor growth. The compound reduced angiogenesis and lymphangiogenesis in models of MDA-MB-231 tumor in the lymph nodes.(Matsui et al, 2008). Lanvatinib provides antitumor activity via inhibition of angiogenesis but also inhibits fibroblast growth factor receptors (FGFR) and RET signaling pathways in preclinical human thyroid cancer models. The compound had antiproliferative activity against the human differentiated thyroid cancer cell line RO82-W-1 and human medullary thyroid cancer TT cell line in vitro (Tohyama et al, 2014).